49 results about "Vitro diagnostics" patented technology

The application discloses a kind of integrated robot latex particle automatic ultrasonic dispersion equipment, including rack, quick-change head device, workpiece fixture rack, ultrasonic water bath and robot;Workpiece fixture rack is equipped with transfer clamp and placement slot, and the movable end of robot is equipped with clamp joint;Robot can drive clamp joint to butt joint or release quick-change head device, and drive quick-change head device to carry out secondary pressing positioning to sample bottle in placement slot;Robot can drive clamp joint to butt joint or release the transfer clamp of workpiece fixture rack, and robot can drive workpiece fixture rack and sample bottle thereon to carry out multidimensional composite motion in ultrasonic water bath.The equipment can realize the semi-automatic linkage operation of "feeding-positioning-ultrasonic dispersion-discharging", reduce manual intervention, guarantee the stability and consistency of latex particle dispersion in sample bottle in large-scale mass production process, significantly improve production efficiency and product quality, and provide key technical support for process upgrading of in-vitro diagnosis industry.

The invention provides a photometric device for a chemiluminescence instrument, and belongs to the technical field of in-vitro diagnosis. The device comprises a mounting base, a light shading unit is fixedly mounted on the mounting base, a light metering piece is fixedly connected to the light shading unit through a light metering fixing piece, a supporting plate is fixedly mounted on the mounting base, a light metering counter is fixedly mounted on the supporting plate, and a light shading piece controlled by a transmission mechanism is slidably mounted in the light shading unit. A cup placing hole is formed in the shading piece, and a reaction cup is placed in the cup placing hole. According to the scheme, the received photon signals are converted into the electric signals through the photometric piece and transmitted to the photometric counter, the photometric counter carries out quantization processing on the electric signals, precise detection of the luminous intensity is achieved, through the design of the integrated cassette, light leakage and signal loss are reduced, the detection sensitivity and the data accuracy are remarkably improved, and the detection accuracy is improved. Meanwhile, the structural layout is simplified, and a foundation is laid for device miniaturization.

The present application relates to a kind of donor reagent in the preparation for the use of kit for the method for diagnosing whether subject is suffered from myocardial injury in vitro, wherein the method comprises: the body fluid from subject is contacted with acceptor reagent and donor reagent, and generates to be measured mixture after reaction;The intensity of signal of chemiluminescence thus produced is detected by exciting the to-be-measured mixture at least once with excitation light;The concentration of at least one myocardial marker in the body fluid is quantitatively calculated according to the intensity of signal of chemiluminescence, to determine whether subject is suffered from myocardial injury;Wherein, the donor reagent includes donor particles capable of generating active oxygen in excited state, and the particle size distribution of the donor particles in the donor reagent presents polydispersity;The surface of the first carrier is not coated or connected with polysaccharide substance, and is directly chemically bonded with one of specific binding pairing members.The method has both ultra-high sensitivity and very wide detection range.

The present application belongs to the pathological diagnosis technical field in vitro diagnosis, technical field, automatic dyeing, automatic sealing is integrated into a whole automatic immunohistochemical dye sealing integrated machine. The automatic immunohistochemical dye sealing integrated machine is used for dyeing and sealing treatment of the glass slide with tissue, comprising a shell, a rack, a dyeing device, a sealing device, a sample loading device, a transfer device and a control device, the dyeing device, the sealing device, the sample loading device and the transfer device are all arranged on the rack and are all electrically connected with the control device, covered by the shell, the dyeing device, the sealing device and the sample loading device are arranged in different regions, the transfer device is movably arranged above the dyeing device, the sealing device and the sample loading device, the dyeing device comprises a dyeing module and a reagent module, and the sealing device comprises a sealing module and a slide cleaning module.

There is provided a particle for the immunoagglutination assay that is a particle for immunoagglutination assay, which includes a diamond particle and a ligand that specifically binds to a biological substance. The ligand is immobilized to the diamond particle, and the particle for the immunoagglutination assay has a particle size of 50 nm or more and 1,000 nm or less.

The invention relates to the technical field of precious metal composite materials, and discloses a composite material with a core-shell structure nanometer material loaded with precious metal nanometer enzyme and a preparation method and application thereof.The preparation method of the material comprises the steps that Au NPs is prepared, specifically, pure water is kept at 100 DEG C for backflow, chloroauric acid is added, sodium citrate is added after boiling is conducted again, and after the reaction is completed, Au NPs is obtained; cooling, centrifuging, washing and resuspending; au NPs modification: dispersing Au NPs in a stabilizer solution, stirring for reaction, centrifugally washing, and resuspending; the preparation method comprises the following steps: adding ammonia water into an Au-coated SiO2: Au ethanol solution, adding TEOS (Tetraethyl Orthosilicate) in a water bath at 30 DEG C for reaction, centrifugally washing, and Preparing Au-coated SiO2-COOH: adjusting the pH value of the Au-coated SiO2 solution, then adding a carboxyl ethyl silanetriol sodium salt solution for reaction, and carrying out centrifugal washing to obtain Au-coated SiO2-COOH; the preparation method comprises the following steps: preparing Au-coated SiO2-COOH-coated NMN: carrying out ultrasonic treatment on Au-coated SiO2-COOH dispersion liquid, adding a noble metal precursor solution, carrying out ice-water bath, adding NaBH4, carrying out a reaction, carrying out centrifugal washing, and re-suspending in pure water to obtain the Au-coated SiO2-COOH-coated NMN. The composite material disclosed by the invention has good chemical stability and good biocompatibility in a complex environment, and can lay a foundation for application in the fields of in-vitro diagnosis, biological catalysis and the like.

The invention provides a metabolic marker combination for diagnosis or auxiliary diagnosis of kidney cancer and application of the metabolic marker combination, and belongs to the technical field of in-vitro diagnosis. The invention provides a metabolic marker combination for diagnosis or auxiliary diagnosis of kidney cancer. The metabolic marker combination comprises L-glucan and aspartic acid, the metabolism marker comprises a blood metabolism marker or a urine metabolism marker. The diagnosis model for distinguishing healthy individuals and kidney cancer patients is constructed by adopting L-glucan and aspartic acid, so that the diagnosis efficiency is high, and the clinical diagnosis significance is realized. In addition, 12 metabolic markers, 10 metabolic markers, 8 metabolic markers, 6 metabolic markers and 4 metabolic markers containing L-glucan and aspartic acid are respectively subjected to construction of diagnosis models for distinguishing healthy individuals from kidney cancer patients, and the constructed diagnosis models have relatively high diagnosis efficiency; the clinical diagnosis significance is realized.

The invention provides a monoclonal antibody aiming at schistosoma japonicum SPRM1hc protein and application of the monoclonal antibody, and belongs to the technical fields of parasite infection treatment, biological medicine, immunotherapy and in-vitro diagnosis. The invention provides two monoclonal antibodies A028 and A032 which can be specifically combined with the extracellular domain of SPRM1hc protein, the actual effect of the monoclonal antibodies A028 and A032 in treatment of schistosoma japonicum katsurada after infection is verified, and the monoclonal antibodies A028 and A032 have a remarkable treatment effect in an infected animal model, and can reduce polypide load, reduce egg deposition and improve tissue pathological damage. The application of the monoclonal antibody to preparation of drugs for resisting schistosoma japonicum katsurada infection and development of schistosoma japonicum katsurada antigen detection kits has very important practical significance.

The invention discloses a biomarker for coronary heart disease diagnosis and / or severity evaluation and application thereof, and relates to the technical field of biomedical detection and in-vitro diagnosis. The biomarker is at least one of a complement C1r and a complement C8, and the invention further provides application of a detection reagent of the biomarker in preparation of products for coronary heart disease diagnosis and / or coronary heart disease severity evaluation, coronary heart disease early screening and coronary heart disease prognosis evaluation. The invention also provides a kit for diagnosing the coronary heart disease and / or evaluating the severity of the coronary heart disease. The complement C1r and the complement C8 can be used as biomarkers for diagnosing the coronary heart disease and evaluating the severity of the coronary heart disease, and the research blank of the complement system in the field of evaluation of the severity of the coronary heart disease is filled. The detection method is based on a blood sample, invasive operation is not needed, the patient risk and the detection cost are reduced, and the method is suitable for clinical large-scale screening and long-term dynamic monitoring.

The invention relates to an antigen construct for rapid immune detection, in particular to an antigen molecule for realizing dimerization or trimerization through foldon or a variant thereof. The antigen construct can enhance the conformation stability and improve the antibody binding efficiency, so that the sensitivity and shelf life stability in colloidal gold, fluorescent microspheres, ELISA (enzyme-linked immuno sorbent assay) and other in-vitro diagnosis methods in immunochromatography are remarkably improved. The construct is suitable for antibody detection of rabies, influenza, coronavirus, Brucella, tuberculosis and the like in zoonosis and HIV, HBV, HCV, syphilis and the like in human infectious diseases, and can be widely applied to clinical screening, animal quarantine, family self-test and public health emergency monitoring.

1. The name of the design product: nucleic acid amplification detection analyzer. 2. The use of the design product: the design product is a nucleic acid amplification detection analyzer, which is used for in vitro diagnosis of nucleic acid amplification detection analysis. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view.

The present application relates to the technical field of in vitro diagnosis protein marker, in particular to a preservative for horseradish peroxidase marker and application thereof. The present application provides a preservative for horseradish peroxidase marker and application thereof. The preservative comprises lecithin 0.05-1.0 g / L, bovine serum albumin 2-10 g / L, sodium chloride 5-30 g / L, polyaspartic acid 2-10 g / L, and the rest is glycerol. The preservative can significantly improve the storage stability of enzyme-labeled product, and the activity of enzyme-labeled antibody can still maintain more than 70% after 21 days of storage at 37 DEG C. In the bottle opening stability test, the activity of enzyme-labeled antibody can maintain more than 87% after 45 days of storage at 4 DEG C.

The present invention relates to a method of detecting and / or quantifying the presence of exons 5 and 6 of ANRIL (Antisense Noncoding RNA in the INK4 Locus) in a subject, comprising the following steps of: 1) Preparation of total RNA from a biological sample of the subject, 2) Conversion of RNA molecules into complementary DNA, 3) Loop-mediated isothermal amplification using trans-exonic oligonucleotides that specifically amplify exons 5 and 6, 4) Addition of Cas12a / RNA guides complexes, wherein RNA guide specifically targets exons 5 and 6 by base pairing, 5) Addition of a reporter DNA probe, 6) Detection of cleavage products, wherein detection of cleavage products reveals the presence of exons 5 and 6 of ANRIL, and 7) possibly quantifying expression of exons 5 and 6 of ANRIL. The present invention also relates to a method for in vitro diagnosis of a cancer in a subject, to a method for in vitro prognosis a cancer in a subject to a kit for implementing the method and to a set of oligonucleotides.

The application provides application of maternal blood exosome miR-1909-3p as a biomarker in preparation of a product for diagnosing or assisting in diagnosing fetal congenital heart disease, and belongs to the technical field of in vitro diagnosis. The application uses miRNA microarray analysis to analyze the expression characteristics of serum exosome microRNAs affected by CHD compared with matched healthy controls. In the early and late pregnancy of TOF fetus, miR-1909-3p is significantly overexpressed in the maternal circulation, indicating that miR-1909-3p is a potential biomarker for fetal congenital heart disease. Through ROC curve analysis of the verification set, it is found that the area under the curve is 0.953, P<0.001, the sensitivity is 95%, and the specificity is 95%, indicating that miR-1909-3p can be used as a potential non-invasive biomarker for prenatal CHD screening.

The present application relates to a tumor risk prediction method and device based on cfDNA nucleosome fingerprint, belonging to the technical field of in vitro diagnosis. Among them, the method comprises: obtaining whole genome sequencing data of plasma or serum cfDNA; the whole genome sequencing data is subjected to quality control processing to remove non-human sequences to obtain human cfDNA sequencing fragments; the human cfDNA sequencing fragments are aligned to the human reference genome to obtain the genomic coordinates of each fragment and the coverage information thereof on the reference genome; based on the whole genome coverage signal, the enrichment region identification algorithm is used to determine the nucleosome positioning boundary, and the peak signal strength is taken as the nucleosome positioning intensity score; the nucleosome positioning intensity score is input into the tumor risk prediction model which has been trained, and the prediction risk probability of the subject suffering from tumor is output. Greatly improve the accuracy of noninvasive screening tumor prediction tumor risk, and the detection cost is low and the cycle is short.

The invention discloses a bigeminy immunoassay kit for detecting an HPV (human papillomavirus) antibody and a preparation method of the bigeminy immunoassay kit, relates to the field of biomedicine, and is characterized in that the bigeminy immunoassay kit for detecting the HPV antibody and the preparation method of the bigeminy immunoassay kit are provided. The magnetic microspheres for detecting the neutralizing antibodies of the human papilloma viruses 16 and 18 are coated with an HPV16 antibody and an HPV18 antigen, acridinium ester is used for marking the HPV16 antigen and the HPV18 antibody, an in-vitro diagnostic kit for detecting the neutralizing antibodies of the human papilloma viruses 16 and 18 is established on the basis, and a chemiluminescence immunoassay method is combined for analysis. The bigeminy immunoassay kit for quantitative detection of the HPV antibody is high in sensitivity, good in specificity, simple and convenient to operate and appropriate in price.

The invention belongs to the technical field of molecular biology and in-vitro diagnosis, and particularly discloses an LAMP (loop-mediated isothermal amplification) primer probe composition for detecting folic acid MTHFR (methylenetetrahydrofolate reductase) gene polymorphism, a kit and application of the LAMP primer probe composition. A probe-mediated LAMP melting curve analysis system is constructed, efficient nucleic acid amplification is realized under a constant-temperature condition by utilizing LAMP reaction, and rapid and accurate typing of C677T mutation sites is realized by combining high-specificity discrimination characteristics of a double-labeled probe melting curve. Compared with a traditional method, the method has the advantages of being short in reaction time, high in sensitivity, high in specificity, free of complex instruments and follow-up operation and the like, and is suitable for clinical rapid typing detection and basic molecular diagnosis application.

The application provides a metabolic marker combination for early kidney cancer diagnosis and application thereof, and belongs to the technical field of in vitro diagnosis. The metabolic marker combination for early kidney cancer diagnosis comprises a first combination or a second combination. The first combination comprises glycyl-L-glutamic acid, L-glutamyl-L-serine, methylphosphatidylcholine 33:2e and triglyceride 54:7. The second combination comprises glycyl-L-glutamic acid, L-glutamyl-L-serine, L-threonyl-L-aspartic acid, iminodiacetic acid, triglyceride 56:8, O-phosphoethanolamine, methylphosphatidylcholine 33:2e and triglyceride 54:7. By detecting the metabolic marker combination in a blood sample, it can be determined whether a patient has early kidney cancer, has high sensitivity and specificity, can realize precise screening of early kidney cancer, and provides important help for prevention and reduction of the incidence of kidney cancer.

This invention relates to the field of molecular biology, specifically to a nested PCR primer set, kit, and application for detecting porcine infectious pleuropneumonia. The kit, developed by establishing a nested PCR amplification primer set, can be used for the in vitro diagnosis of porcine infectious pleuropneumonia. It exhibits high sensitivity, detecting up to 0.355 pg / µL, which is nearly 100 times higher than that of conventional PCR (35.5 pg / µL). It also demonstrates strong specificity, overcoming the problems of low sensitivity and poor specificity associated with conventional PCR. Compared to existing indirect immunofluorescence and serological detection methods, it offers lower cost and a shorter detection cycle.

The invention discloses a double logarithmic calibration method based on a reagent for a blood coagulation analyzer, and relates to the technical field of in vitro diagnosis, and the method comprises the following steps: based on the deviation of temperature and turbidity, performing fractional normalization anti-interference correction on a detection signal through a detection signal correction function, obtaining a corrected detection signal, and generating a corrected detection signal curve; combining the corrected detection signal with an initial double logarithm calibration equation to generate a predicted concentration, comparing the predicted concentration with a reference concentration to obtain a concentration deviation, and generating an anti-interference correction response amount according to the solidification time in the corrected detection signal curve; on the basis of the anti-interference correction response quantity, calculating a double logarithmic residual error of the test sample, associating the double logarithmic residual error with the concentration deviation, and performing real-time step length adjustment on a coefficient in a detection signal correction function according to a residual error direction to generate an updated double logarithmic calibration equation. According to the invention, the accuracy and robustness of the double logarithmic calibration equation are improved.

The application discloses an isolated microRNA molecule, a DNA hexagon-based Parkinson's disease in-vitro diagnosis kit and application thereof. The microRNA molecule miR26690 provided by the application is highly expressed in exosomes in peripheral blood of Parkinson's disease patients, and can be used for in-vitro diagnosis and / or screening of Parkinson's disease. In addition, the kit and method for detecting miR26690 in peripheral blood provided by the application can detect miR26690 in peripheral blood with high sensitivity and high specificity, and compared with a traditional Parkinson's disease marker detection method, the method is simple, easy to prepare, has a small sample amount, is higher in sensitivity, has a low detection limit and is low in detection cost.

The invention discloses application of Der p sIgE and / or Der f sIgE in nasal secretion in preparation of a kit or a detection platform for diagnosing local allergic rhinitis, and relates to the technical field of in vitro diagnosis and immunoassay. The invention relates to application of Der p sIgE and / or Der f sIgE in nasal secretion in preparation of a kit or a detection platform for diagnosing local allergic rhinitis. The invention proposes and verifies that the dust mite sIgE in the nasal secretion can be used as an effective biomarker for diagnosing LAR for the first time, and solves the technical problem of difficulty in typing serum sIgE negative rhinitis patients clinically. Detection can be completed only by collecting nasal secretions, operation is easy and convenient, safety is high, and clinical popularization is easy. According to the method, diagnosis is objective and accurate, a diagnosis critical value is scientifically established through research on healthy people, a quantitative objective diagnosis standard is provided, it is verified through the cell factor level that the diagnosis result is highly consistent with the intrinsic biological mechanism of allergic inflammation, and the accuracy is high.

The invention belongs to the technical field of in-vitro diagnosis, and particularly relates to a sample diluent as well as a preparation method, application and a product thereof. The invention provides a sample diluent. The sample diluent is composed of a stabilizer, glucose, poloxamer, a nonionic surfactant, a biological preservative, a metal ion salt and a buffer solution. The sample diluent provided by the invention can effectively solve the problems of high background, poor detection specificity, low stability and the like caused by binding of EDTA and quantum dot divalent metal ions in an EDTA anticoagulant plasma sample, and the detection sensitivity and specificity are remarkably improved. The sample diluent is suitable for preparing Alzheimer's disease diagnostic reagents, kits or chips, can accurately detect beta amyloid protein, phosphorylated Tau protein, blood protein and other markers in plasma, is especially suitable for EDTA anticoagulant plasma sample detection, and provides reliable basis for clinical diagnosis.

The present application relates to the technical field of in vitro diagnosis, in particular to plasmin-alpha2 plasmin inhibitor complex determination reagent and application thereof.The present application provides plasmin-alpha2 plasmin inhibitor complex determination reagent, which comprises magnetic particle suspension and labeled antibody mixture.The magnetic particle suspension comprises plasmin-alpha2 plasmin inhibitor complex antibody coated magnetic particles and magnetic particle buffer.The labeled antibody mixture comprises tracer labeled plasmin-alpha2 plasmin inhibitor complex antibody and labeled antibody buffer.The magnetic particle buffer and the labeled antibody buffer comprise buffer system, stabilizer and preservative.The reagent combination provided by the present application has high accuracy and good repeatability, and is suitable for popularization and application.

The present invention relates to compositions and methods for detecting and treating ovarian cancer, including methods for in vitro diagnosis of ovarian cancer, and to compositions and methods for preventing or treating ovarian cancer, wherein the compositions comprise antibodies that bind progastrin and the methods comprise the use of antibodies that bind progastrin.

The utility model provides a storage module, a storage assembly and a sample rack storage device, and relates to the technical field of in vitro diagnos.The storage module comprises a module body, a plurality of module partition plates and limiting elements, the module body is internally provided with a storage space, and the module partition plates are arranged in the storage space; the storage space of the module body is divided into a plurality of storage bins through a plurality of module partition plates, each storage bin is provided with a bin opening, each bin opening comprises a longitudinal top opening and a transverse in-out opening, and the storage bins are used for being moved in or out of the sample frame through the in-out openings. And the limiting element shields at least one part of opening area of the top opening and is used for limiting the longitudinal movement of the sample rack in the storage bin. The limiting element can limit the longitudinal movement of the sample frame in the storage bin in the Z-axis direction, and the situation that the sample frame moves in the storage bin, and consequently the position of the sample frame is not accurate is avoided.

The present application relates to the technical field of in vitro diagnosis, and particularly relates to an antigen epitope peptide of Helicobacter pylori vacuolating cytotoxin in feces and application thereof. The amino acid sequence of the antigen epitope peptide comprises one or more of DTV, DMK and WRI. By using the antigen epitope peptide provided in the present application, more specific antibodies against different antigen epitopes of VacA can be obtained, so that the accuracy of immunological methods for detecting the degradation product of VacA in feces is improved, the detection time of Helicobacter pylori infection is greatly saved, and the human body is not damaged during sampling.

The invention discloses an enzyme signal amplified mycobacterium rapid detection kit and a detection method, and relates to the technical field of in vitro diagnosis. Aiming at the current situations that a culture method is time-consuming, PCR (Polymerase Chain Reaction) equipment is expensive and a rapid detection strip is low in sensitivity, the invention provides an enzyme signal amplified mycobacterium rapid detection kit and a detection method, an upper cover and a lower cover of a shell are buckled to form a cavity, a chromatography strip assembly is attached to a PVC (Polyvinyl Chloride) back plate in the cavity, the assembly is formed by sequentially overlapping a sample adding pad, a combining pad, an NC (Nitrocellulose) membrane and an absorbing pad, and a T line and a C line are arranged on the NC membrane; an HRP labeled antibody is pre-embedded in the conjugate pad, and after detection, a chromogenic substrate is dropwise added to trigger multiple rounds of enzymatic reaction amplification signals. The structure is matched with an annular sealing ring and a drying agent, interpretation can be performed by naked eyes or a reading instrument within 15 min, the lowest detection limit reaches 10-12 CFUmL, the false negative risk of low bacterial quantity is reduced, and the rapid screening requirement of a basic level site is met.